Novartis may put a $4 million to $5 million price tag on its “one-time, potentially curative” gene therapy AVXS-101 for spinal muscular atrophy (SMA) and believes this could be cost-effective. “Four million dollars is a significant amount of money, but we believe that this is a cost-effective point,”…
News
A 3-D cell model derived from patients’ stem cells is able to mimic motor neurons from spinal muscular atrophy (SMA) patients and can become a better physiological tool to study disease mechanisms and screen therapy candidates, new research shows. The study,…
Establishing care coordinators is key to providing successful family-centered care to young spinal muscular atrophy (SMA) type 1 patients and their families, according to a recent study. The study, “Identifying Opportunities to Provide Family-centered Care for Families With Children With Type 1 Spinal Muscular Atrophy,” was published…
Researchers have successfully generated stable lines of spinal cord neural stem cells (NSCs), which, when transplanted into a rat model of spinal cord injury, were able to become multiple types of neurons and drive spine regeneration. Derived from human embryonic stem cells (hESCs), these induced cells also included progenitors that give rise…
Preliminary data from two ongoing clinical trials into risdiplam (RG7916) — a potential oral therapy for all types of spinal muscular atrophy — support its considerable promise, with treated babies now able to “roll, sit, kick … things that they [otherwise] never do,” the CEO of PTC Therapeutics said in…
With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Creditand affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate, or…
Specific patterns of DNA modifications in the DYNC1H1 gene are directly associated with spinal muscular atrophy severity in different forms of the disease. These findings could be the first step toward the identification of new SMA modifiers. The study, “DYNC1H1 gene methylation correlates with severity of spinal muscular…
MRC Holland has launched a newborn screening test, called SALSA MC002 SMA Newborn Screen, that uses a blood sample to detect a specific SMN1 gene alteration that underlies spinal muscular atrophy (SMA). The first in the company’s SALSA Melt Assay product line, this assay can reliably, quickly and…
Patient enrollment is complete for AveXis’ Phase 1 clinical trial testing its gene therapy candidate AVXS-101 in patients with spinal muscular atrophy (SMA) type 2. “We are pleased that STRONG is now fully-enrolled and expect to report data from this study by May 2019,” David Lennon, PhD, the company’s president,…
Novartis Pharmaceuticals‘ investigational compound BVS857 significantly improved muscle volume in patients with X-linked type spinal muscular atrophy (SMA) over a short period of time, Phase 2 clinical results show. However, the compound failed to improve muscle strength and function. These findings were reported in the study, “…
